相关实验视频
Updated: Jun 25, 2025

07:01
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
21.1K
在甲状腺癌中药物重新定位:从点突变到基因融合
David Sánchez-Marín1, Macrina Beatriz Silva-Cázares2, Manuel González-Del Carmen3
1Posgrado en Ciencias Biológicas, Facultad de Medicina, Universidad Nacional Autónoma de Mexico (UNAM), Ciudad de Mexico, Mexico.
Frontiers in oncology
|May 23, 2024
概括
甲状腺癌 (TC) 治疗耐药性是常见的. 本综述探讨了基因组变异和融合基因作为药物重新定位的潜在目标,以提高甲状腺癌患者的化疗疗效率.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲状腺癌 (TC) 诊断正在上升,乳头TC是最常见的类型.
- 已建立的治疗方法包括手术,激素治疗,放射性,化疗和向治疗.
- 治疗耐药性影响约20%的TC病例,需要新的治疗策略.
研究的目的:
- 审查甲状腺癌中潜在的可用药物基因组变异.
- 确定融合基因作为TC中新兴的治疗点.
- 为TC中点变异和融合基因提出药物重新定位策略.
主要方法:
- 在甲状腺癌中对基因组测序数据的文献综述.
- 对已识别的点突变和染色体重排的分析.
- 对现有的向疗法进行评估,以潜在的重新定位.
主要成果:
- 基因组测序揭示了可以赋予化疗耐药性的变体.
- 导致融合基因的染色体重组在癌症中越来越被认可,但在TC中未得到充分研究.
- 几种点变异和融合基因为向药物开发提供了机会.
结论:
- 识别可用药的变体和融合基因对于推进TC治疗至关重要.
- 药物重新定位提供了一个有希望的途径,以克服TC的治疗耐药性.
- 针对点突变和融合基因,可以提高甲状腺癌的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Conservative Site-specific Recombination and Phase Variation
6.0K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K

